Low Leverage / Strong Balance SheetA very high equity ratio and minimal debt provide durable financial flexibility: the company can fund working capital, absorb regulatory or market setbacks, and pursue capacity or product investments without heavy refinancing risk, supporting multi‑month resilience.

Healthy Margins & Return To ProfitabilitySustained gross margins near 41% and a positive net margin indicate structural cost control and pricing strength in its API and formulation mix. Durable margins improve cash generation potential (if converted) and allow reinvestment into R&D or capacity to sustain competitive position over months.

Reported Revenue GrowthA reported ~12.5% annual revenue gain suggests expanding market penetration or mix improvement across APIs and formulations. Stable top‑line growth supports better fixed‑cost absorption in manufacturing and provides a firmer base for margin and earnings stability over the medium term.

Bears Say

Negative Free Cash FlowNegative free cash flow is a durable concern: it constrains the company's ability to self‑fund capex, new product launches, or working capital needs. If sustained, it forces reliance on external financing or equity, raising cost of capital and limiting strategic optionality over coming months.

Weak Cash ConversionAn OCF-to-net-income ratio of 0.19 means reported profits largely do not translate into cash, likely from working capital pressure or receivables. This weak conversion increases operational risk, reduces financial flexibility, and makes earnings less reliable for funding growth or paying down obligations.

Modest Return On EquityAn ROE below 8% signals only moderate efficiency in converting shareholder capital into profits versus peers. Over months this can limit the company's ability to deliver compelling shareholder returns, and may reflect capital intensity or underutilized assets that constrain scalable profit growth.

Orchid Pharma Limited News

Orchid Pharma’s 32nd AGM: Virtual Meeting and Voting Results Announced

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has issued an update. Orchid Pharma Limited announced the results of its...

6M ago

ORCHPHARMA FAQ

What was Orchid Pharma Limited’s price range in the past 12 months?

Orchid Pharma Limited lowest stock price was ₹488.80 and its highest was ₹898.45 in the past 12 months.

What is Orchid Pharma Limited’s market cap?

Orchid Pharma Limited’s market cap is ₹25.99B.

When is Orchid Pharma Limited’s upcoming earnings report date?

Orchid Pharma Limited’s upcoming earnings report date is May 07, 2026 which is in 52 days.

How were Orchid Pharma Limited’s earnings last quarter?

Orchid Pharma Limited released its earnings results on Feb 11, 2026. The company reported -₹2.487 earnings per share for the quarter, missing the consensus estimate of -₹0.3 by -₹2.187.

Is Orchid Pharma Limited overvalued?

According to Wall Street analysts Orchid Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Orchid Pharma Limited pay dividends?

Orchid Pharma Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Orchid Pharma Limited dividends here

What is Orchid Pharma Limited’s EPS estimate?

Orchid Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Orchid Pharma Limited have?

Orchid Pharma Limited has 50,719,105 shares outstanding.

What happened to Orchid Pharma Limited’s price movement after its last earnings report?

Orchid Pharma Limited reported an EPS of -₹2.487 in its last earnings report, missing expectations of -₹0.3. Following the earnings report the stock price went up 0.189%.

Which hedge fund is a major shareholder of Orchid Pharma Limited?

Currently, no hedge funds are holding shares in IN:ORCHPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Orchid Pharma Limited

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company's multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. In addition, the company provides liaising support to customers in regulatory, pharma covigilance, testing and release, retention of samples, service providers, and business development. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited is a subsidiary of Dhanuka Laboratories Limited.